Krystal Biotech, Inc.

DB:4KB Stock Report

Market Cap: €4.4b

Krystal Biotech Management

Management criteria checks 3/4

Krystal Biotech's CEO is Krish Krishnan, appointed in Dec 2015, has a tenure of 9.08 years. total yearly compensation is $6.22M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 5.35% of the company’s shares, worth €234.66M. The average tenure of the management team and the board of directors is 3 years and 6.6 years respectively.

Key information

Krish Krishnan

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage11.8%
CEO tenure9.1yrs
CEO ownership5.3%
Management average tenure3yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Krish Krishnan's remuneration changed compared to Krystal Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$52m

Jun 30 2024n/an/a

US$106m

Mar 31 2024n/an/a

US$57m

Dec 31 2023US$6mUS$733k

US$11m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$3mUS$645k

-US$140m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$104m

Dec 31 2021US$7mUS$581k

-US$70m

Sep 30 2021n/an/a

-US$58m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$764kUS$498k

-US$32m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$631kUS$366k

-US$19m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$13m

Dec 31 2018US$705kUS$200k

-US$11m

Compensation vs Market: Krish's total compensation ($USD6.22M) is above average for companies of similar size in the German market ($USD1.89M).

Compensation vs Earnings: Krish's compensation has been consistent with company performance over the past year.

CEO

Krish Krishnan (59 yo)

9.1yrs

Tenure

US$6,223,894

Compensation

Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since December 2015. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. K...

Leadership Team

NamePositionTenureCompensationOwnership
Krish Krishnan
Founder9.1yrsUS$6.22m5.35%
€ 234.7m
Suma Krishnan
Founder9.1yrsUS$3.84m5.44%
€ 239.0m
Kathryn Romano
Executive VP & Chief Accounting Officer5yrsUS$2.57m0.045%
€ 2.0m
John Thomas
General Counsel & Corporate Secretaryno datano datano data
John Karakkal
Vice President of North American Sales & Marketingno datano datano data
Christine Wilson
Head of U.S. Sales & Marketingless than a yearno datano data
Stephane Paquette
Vice President of Corporate Developmentno datano datano data
Josh Suskin
Director of Human Resources & Operationsno datano datano data
Laurent Goux
Senior VP & GM of Europeno datano datano data
David Chien
Senior Vice President of Clinical Development3yrsno datano data
Jennifer McDonough
Senior Vice President of Patient Accessless than a yearno datano data
Ramesh Arjunji
Senior Vice President of Global Value and Accessless than a yearno datano data

3.0yrs

Average Tenure

59yo

Average Age

Experienced Management: 4KB's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Krish Krishnan
Founder9.1yrsUS$6.22m5.35%
€ 234.7m
Suma Krishnan
Founder9yrsUS$3.84m5.44%
€ 239.0m
Daniel Janney
Lead Independent Director8.2yrsUS$610.32k0.37%
€ 16.4m
Dino Rossi
Independent Director7.6yrsUS$584.82k0.27%
€ 12.0m
Julian Gangolli
Independent Director5.8yrsUS$585.07kno data
E. Sutherland
Independent Director3yrsUS$570.44k0%
€ 0
Christopher Mason
Independent Director4yrsUS$568.32k0%
€ 0
Kirti Ganorkar
Non-Employee Independent Director7.3yrsno datano data
Catherine Mazzacco
Independent Director1.8yrsUS$934.43k0%
€ 0
Samuel Broder
Chairman of Scientific Advisory Board5yrsno datano data

6.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 4KB's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:41
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Krystal Biotech, Inc. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Alec StranahanBofA Global Research
Justin ZelinB. Riley Securities, Inc.